Pages that link to "Item:Q3436524"

The following pages link to Bayesian Dose-Finding in Phase I/II Clinical Trials Using Toxicity and Efficacy Odds Ratios (Q3436524):

Displaying 33 items.

• Bayesian phase I/II adaptively randomized oncology trials with combined drugs (Q641145) (← links)
• Bayesian phase II adaptive randomization by jointly modeling time-to-event efficacy and binary toxicity (Q746098) (← links)
• A Bayesian dose-finding design for drug combination trials with delayed toxicities (Q908029) (← links)
• A Bayesian phase I/II clinical trial design in the presence of informative dropouts (Q1747447) (← links)
• Efficacy and toxicity monitoring via Bayesian predictive probabilities in phase II clinical trials (Q2059113) (← links)
• Bayesian hierarchical random-effects meta-analysis and design of phase I clinical trials (Q2080762) (← links)
• Flexible link continual reassessment methods for trivariate binary outcome phase I/II trials (Q2320854) (← links)
• Sequential Monte Carlo for Bayesian sequentially designed experiments for discrete data (Q2359487) (← links)
• Adaptive designs for selecting drug combinations based on efficacy-toxicity response (Q2475724) (← links)
• Adaptive designs for dose-finding based on efficacy-toxicity response (Q2492921) (← links)
• Bayesian dose finding for combined drugs with discrete and continuous doses (Q2633955) (← links)
• A Bayesian Approach to Dose-Response Assessment and Synergy and Its Application to In Vitro Dose-Response Studies (Q3076068) (← links)
• On the Use of Nonparametric Curves in Phase I Trials with Low Toxicity Tolerance (Q3078934) (← links)
• A New Dose‐Finding Design for Bivariate Outcomes (Q3433237) (← links)
• A Bayesian Phase I/II Trial Design for Immunotherapy (Q4559685) (← links)
• Simple benchmark for complex dose finding studies (Q5170208) (← links)
• A Three-Stage Bayesian Adaptive Phase I/II Design and Simulation Studies (Q5417921) (← links)
• (Q5434036) (← links)
• Implementation of a Bayesian Design in a Dose‐Escalation Study of an Experimental Agent in Healthy Volunteers (Q5450494) (← links)
• (Q5714616) (← links)
• DICE: A Bayesian model for early dose finding in phase I trials with multiple treatment courses (Q6068878) (← links)
• A Bayesian adaptive phase I/II clinical trial design with late‐onset competing risk outcomes (Q6076490) (← links)
• Bayesian dose regimen assessment in early phase oncology incorporating pharmacokinetics and pharmacodynamics (Q6079344) (← links)
• Adaptive Bayesian phase I clinical trial designs for estimating the maximum tolerated doses for two drugs while fully utilizing all toxicity information (Q6085905) (← links)
• DROID: dose-ranging approach to optimizing dose in oncology drug development (Q6589229) (← links)
• REDOMA: Bayesian random-effects dose-optimization meta-analysis using spike-and-slab priors (Q6618357) (← links)
• A Bayesian phase I/II platform design for co-developing drug combination therapies for multiple indications (Q6622241) (← links)
• A Bayesian design for phase I cancer therapeutic vaccine trials (Q6625928) (← links)
• A utility-based Bayesian optimal interval (U-BOIN) phase I/II design to identify the optimal biological dose for targeted and immune therapies (Q6627253) (← links)
• A phase I--II design based on periodic and continuous monitoring of disease status and the times to toxicity and death (Q6627403) (← links)
• uTPI: a utility-based toxicity probability interval design for phase I/II dose-finding trials (Q6627822) (← links)
• A Bayesian adaptive phase i/II platform trial design for pediatric immunotherapy trials (Q6627894) (← links)
• TITE-BOIN12: a Bayesian phase I/II trial design to find the optimal biological dose with late-onset toxicity and efficacy (Q6628336) (← links)